|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAGOH |
 Gene summary |
| Basic gene Info. | Gene symbol | MAGOH |
| Gene name | mago-nashi homolog, proliferation-associated (Drosophila) | |
| Synonyms | MAGOH1|MAGOHA | |
| Cytomap | UCSC genome browser: 1p32.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_002370.3, | |
| Description | protein mago nashi homolog | |
| Modification date | 20141211 | |
| dbXrefs | MIM : 602603 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000162385 | ||
| HPRD : 04005 | ||
| Vega : OTTHUMG00000008932 | ||
| Protein | UniProt: P61326 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAGOH | |
| BioGPS: 4116 | ||
| Pathway | NCI Pathway Interaction Database: MAGOH | |
| KEGG: MAGOH | ||
| REACTOME: MAGOH | ||
| Pathway Commons: MAGOH | ||
| Context | iHOP: MAGOH | |
| ligand binding site mutation search in PubMed: MAGOH | ||
| UCL Cancer Institute: MAGOH | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for MAGOH |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D66 | D66N | BLCA | 1 | R82 | R82Q | BLCA | 1 | D66 | D66N | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAGOH |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R82 | R82Q | -1.4737802 | D66 | D66N | -1.0225694 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAGOH from PDB |
| Top |
| Differential gene expression and gene-gene network for MAGOH |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAGOH |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAGOH |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAGOH go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (ILE,ARG,ASN,LYS,ASP,ARG,PRO,ALA,MET,GLN,LEU,TYR,GLN,PRO,GLY) | 2xb2 | C | D66 | III | Peptide ligand (HIS,LEU,ASP,ASP,ASP,GLU,ASP,ARG,LYS,ASN,PRO,ALA,TYR,ILE,PRO,ARG,LYS,GLY,LEU,PHE,PHE,GLU,HIS,ASP,LEU,ARG,GLY,GLN) | 2j0s | C | R82 |
| Top |
| Conservation information for LBS of MAGOH |
| Multiple alignments for P61326 in multiple species |
| LBS | AA sequence | # species | Species | D66 | KRIIDDSEITK | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | F17 | GHKGKFGHEFL | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | G15 | YVGHKGKFGHE | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | H13 | RYYVGHKGKFG | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | K16 | VGHKGKFGHEF | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | K41 | NNSNYKNDVMI | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | L107 | SKIGSLIDVNQ | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | R82 | WPPPDRVGRQE | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | V83 | PPPDRVGRQEL | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus | Y40 | ANNSNYKNDVM | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Gallus gallus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |